4/4
05:13 pm
mrsn
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
4/4
04:05 pm
mrsn
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
4/1
08:01 am
mrsn
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
Medium
Report
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
3/6
06:58 am
mrsn
Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates [Yahoo! Finance]
Medium
Report
Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates [Yahoo! Finance]
3/5
06:39 am
mrsn
Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts [Yahoo! Finance]
Medium
Report
Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts [Yahoo! Finance]
3/4
07:07 pm
mrsn
Mersana Therapeutics Full Year 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Mersana Therapeutics Full Year 2024 Earnings: Beats Expectations [Yahoo! Finance]
3/3
12:17 pm
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
Medium
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
3/3
07:01 am
mrsn
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
High
Report
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
2/28
07:26 am
mrsn
What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings [Yahoo! Finance]
Low
Report
What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings [Yahoo! Finance]
2/25
08:00 am
mrsn
Mersana Therapeutics to Present at Upcoming Investor Conferences
Medium
Report
Mersana Therapeutics to Present at Upcoming Investor Conferences
2/24
04:01 pm
mrsn
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
Medium
Report
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
2/7
04:05 pm
mrsn
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/6
07:33 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Medium
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
1/30
08:15 am
mrsn
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference [Yahoo! Finance]
Medium
Report
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference [Yahoo! Finance]
1/30
08:00 am
mrsn
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Medium
Report
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
1/10
08:13 pm
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock, down previously from $7.00.
High
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock, down previously from $7.00.
1/10
06:02 am
mrsn
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
High
Report
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
1/10
06:00 am
mrsn
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer
High
Report
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer